Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Hart

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Blood Advances|August 10, 2022
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 studyOlga Oleshko, Sonja Werwitzke, Annika Klingberg, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
BMJ Case Reports|June 30, 2011
Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) in fulminant blastomycosis in GermanyMarkus Resch, Katrin Kurz, Wulf Schneider-Brachert, et al.
Haematologica|March 28, 2024
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignanciesMarkus Perl, Konstantin Herfeld, Dennis C Harrer, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
Therapeutic Advances in Hematology|December 2, 2024
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiaryCarmen Escuriola Ettingshausen, Wolfgang Eberl, Hermann Eichler, et al.
Blood Advances|August 12, 2025
Sustained Survival Benefit of Emicizumab and Postponed Immunosuppression in Acquired Hemophilia AInga M Schimansky, Christiane Dobbelstein, Robert Klamroth, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 26, 2025
Five-Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis ResearchHermann Eichler, Hagen Bönigk, Susan Halimeh, et al.
Haematologica|November 13, 2025
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxisFabius J Pelzer, Ella I Ertekin, Olga Oleshko, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Blood Advances|August 10, 2022
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 studyOlga Oleshko, Sonja Werwitzke, Annika Klingberg, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
BMJ Case Reports|June 30, 2011
Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) in fulminant blastomycosis in GermanyMarkus Resch, Katrin Kurz, Wulf Schneider-Brachert, et al.
Haematologica|March 28, 2024
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignanciesMarkus Perl, Konstantin Herfeld, Dennis C Harrer, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
Therapeutic Advances in Hematology|December 2, 2024
Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiaryCarmen Escuriola Ettingshausen, Wolfgang Eberl, Hermann Eichler, et al.
Blood Advances|August 12, 2025
Sustained Survival Benefit of Emicizumab and Postponed Immunosuppression in Acquired Hemophilia AInga M Schimansky, Christiane Dobbelstein, Robert Klamroth, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 26, 2025
Five-Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis ResearchHermann Eichler, Hagen Bönigk, Susan Halimeh, et al.
Haematologica|November 13, 2025
Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxisFabius J Pelzer, Ella I Ertekin, Olga Oleshko, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
Pageof 6